Braintree Takes Cypress To Court Over Generic Suprep

Law360, New York (September 12, 2012, 5:04 PM EDT) -- Braintree Laboratories Inc. hit Cypress Pharmaceutical Inc. with a patent suit Tuesday in New York federal court seeking to block Cypress from marketing a generic version of the laxative drug Suprep.

According to the complaint, Cypress notified Braintree on July 31 that it had submitted an abbreviated new drug application to the U.S. Food and Drug Administration for a generic version of Suprep.

Braintree claims that the ANDA filing infringed its patent on the drug and that it is entitled to a court order that the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.